$104.92
0.37% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US53220K5048
Symbol
LGND

Ligand Pharmaceuticals Incorporated Stock price

$104.92
+0.11 0.11% 1M
-6.64 5.95% 6M
-2.23 2.08% YTD
+18.29 21.11% 1Y
+54.38 107.58% 3Y
+41.95 66.61% 5Y
+52.00 98.25% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.39 0.37%
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Key metrics

Market capitalization $2.02b
Enterprise Value $1.82b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 36.05
EV/Sales (TTM) EV/Sales 10.03
P/S ratio (TTM) P/S ratio 11.15
P/B ratio (TTM) P/B ratio 2.54
Revenue growth (TTM) Revenue growth 53.40%
Revenue (TTM) Revenue $181.49m
EBIT (operating result TTM) EBIT $-16.63m
Free Cash Flow (TTM) Free Cash Flow $50.48m
Cash position $208.90m
EPS (TTM) EPS $-7.12
P/E forward 765.04
P/S forward 10.43
EV/Sales forward 9.38
Short interest 7.68%
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
100%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
181 181
53% 53%
100%
- Direct Costs 46 46
9% 9%
25%
135 135
79% 79%
75%
- Selling and Administrative Expenses 49 49
210% 210%
27%
- Research and Development Expense 66 66
169% 169%
36%
21 21
42% 42%
11%
- Depreciation and Amortization 37 37
1% 1%
21%
EBIT (Operating Income) EBIT -17 -17
1,091% 1,091%
-9%
Net Profit -133 -133
238% 238%
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Neutral
Investors Business Daily
one day ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
GlobeNewsWire
7 days ago
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025.
Neutral
Seeking Alpha
12 days ago
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chief Executive Officer Rich Baxter – Senior Vice President-Investment Operations Tavo Espinoza – Chief Financial Officer Lauren Hay – Vice President-Strategic Planning and Investment Analytics Confere...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 68
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today